Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
06/09/2019Notice of General Meeting/Proxy FormDownload
27/08/2019Appendix 3BDownload
27/08/2019Cleansing NoticeDownload
23/08/2019Appendix 4E & Annual ReportDownload
23/08/2019Appendix 4GDownload
20/08/2019Change in substantial holdingDownload
20/08/2019Appendix 3BDownload
20/08/2019Cleansing NoticeDownload
20/08/2019Information Required under ASX Listing Rule 3.10.5ADownload
20/08/2019Becoming a substantial holderDownload
1  2  3  4  5  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier